Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Notes Payables (2016 - 2025)

Guided Therapeutics' Notes Payables history spans 15 years, with the latest figure at $145000.0 for Q3 2025.

  • For Q3 2025, Notes Payables fell 36.4% year-over-year to $145000.0; the TTM value through Sep 2025 reached $145000.0, down 36.4%, while the annual FY2024 figure was $139000.0, 135.59% up from the prior year.
  • Notes Payables for Q3 2025 was $145000.0 at Guided Therapeutics, up from $24000.0 in the prior quarter.
  • Across five years, Notes Payables topped out at $350000.0 in Q2 2022 and bottomed at $11000.0 in Q1 2021.
  • The 5-year median for Notes Payables is $71081.0 (2023), against an average of $98406.3.
  • The largest annual shift saw Notes Payables skyrocketed 16000.0% in 2021 before it crashed 71.14% in 2025.
  • A 5-year view of Notes Payables shows it stood at $161000.0 in 2021, then crashed by 64.86% to $56569.0 in 2022, then rose by 4.3% to $59000.0 in 2023, then soared by 135.59% to $139000.0 in 2024, then increased by 4.32% to $145000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Notes Payables are $145000.0 (Q3 2025), $24000.0 (Q2 2025), and $48000.0 (Q1 2025).